Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

MK Techno. -O-
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
Poslední obchod Změna (%) Změna Objem obchodů ()
- - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiMauna Kea Technologies SAS
TickerMKEA
Kmenové akcie:Ordinary Shares
RICMKEA.PA
ISINFR0010609263
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.12.2019
Počet zaměstnanců k 30.06.2019 99
Akcie v oběhu k 30.06.2019 25 156 296
MěnaEUR
Kontaktní informace
Ulice9, rue d'Enghien
MěstoPARIS
PSČ75010
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 148 240 345
Fax33148241218

Business Summary: Mauna Kea Technologies SAS, also known as Mauna Kea Technologies SA, is a France-based company active in the healthcare business sector. It specializes in designing, developing, and selling medical imaging tools and systems. The Company’s products, used mainly in endoscopy, are intended for viewing and detecting deficiencies in the gastrointestinal and respiratory systems, primarily focusing on patients suffering from cancer. The main product offered by the Company is Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) which is a system providing physicians and researchers with high resolution cellular images of tissue in a real-time structure. The Company has marketing authorizations in Thailand, the United Kingdom, the USA, Brazil, Chile, South Korea, Poland, Russia and Saudi Arabia, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2019, Mauna Kea Technologies SAS revenues increased 45% to EUR3.9M. Net loss increased 18% to EUR8.1M. Revenues reflect Miniprobe segment increase of 72% to EUR2.1M, Equipment segment increase of 36% to EUR1.3M, China segment increase from EUR506K to EUR1.4M, Americas segment increase of 40% to EUR1.9M. Higher net loss reflects Discounting expenses increase from EUR72K to EUR1.2M (expense).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology - NEC
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
SICElectromedical Equipment
SICSurgical And Medical Instruments



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardSacha Loiseau-22.10.2018
Chief Executive Officer, DirectorRobert Gershon5122.10.201822.10.2018
Deputy Chief Executive Officer, Chief Financial OfficerChristophe Lamboeuf-22.10.2018
Chief Scientific OfficerFrancois Lacombe-01.01.2005
Vice President of International SalesBruno Villaret-
Director of Research & DevelopmentMarion Ghibaudo-01.01.2018
Director of Human ResourcesSeverine Cadiou-01.01.2017
Regulatory and Clinical Affairs and Scientific Communication DirectorAline Criton-
Director of OperationsVeronique Dentan-